Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$57.88T
24h Vol:
$10.32B
Dominance:
MSFT:5.17%
Stocklytics Platform
BETA
Instrument logo  VVOS

Vivos Therapeutics, Inc.

VVOS
54 / 100
$5.25arrow_drop_down-2.05%-$0.11

Performance History

Stocklytics logo
Key Stats
Open$5.64
Prev. Close$5.36
EPS-13.19
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap6992895.00
PE Ratio-
LOWHIGH
Day Range5.16
5.64
52 Week Range0.18
48.79
Ratios
P/B Ratio146.81
Revenue$14.50M
Operating M. %-110.27%
Earnings$0.00
Earnings Growth %35.36%
EBITDA Margin %-128.15%
ROE %-311.34%
EPS-13.19

Score Breakdown

54vs 52. Market Avg.

All Score 54 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

VVOSMARKET
Value4639
Quality3540
Ownership1319
Growth6345
Dividends-38
check_circle

Vivos Therapeutics, Inc.'s Price growth average in the last 3 years of 107.71% is great compared to market average of 6.07%. This indicates VVOS could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$781.75
24H (%)arrow_drop_up3.16%
24H ($)$23.96
MARKET CAP$742.16B
PRICE$521.35
24H (%)arrow_drop_up0.09%
24H ($)$0.47
MARKET CAP$482.16B
PRICE$156.53
24H (%)arrow_drop_down-0.88%
24H ($)-$1.39
MARKET CAP$376.76B
PRICE$127.68
24H (%)arrow_drop_up0.90%
24H ($)$1.14
MARKET CAP$323.55B

About Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.

Sector
Healthcare
Industry
Medical Devices
CEO
Mr. R. Kirk Huntsman
Headquarters
Littleton
Employees
154
Exchange
NASDAQ
add Vivos Therapeutics, Inc. to watchlist

Keep an eye on Vivos Therapeutics, Inc.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
What is Vivos Therapeutics, Inc.'s (VVOS) price per share?

The current price per share for Vivos Therapeutics, Inc. (VVOS) is $5.13. The stock has seen a price change of -$0.12 recently, indicating a -2.29% change. This reflects the stock's recent market performance and investor sentiment.

question_mark
What is the 52-week high and low for Vivos Therapeutics, Inc. (VVOS)?

For Vivos Therapeutics, Inc. (VVOS), the 52-week high is $48.79, which is 851.07% from the current price. The 52-week low is $0.18, the current price is 2.75K% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

question_mark
Is Vivos Therapeutics, Inc. (VVOS) a growth stock?

Vivos Therapeutics, Inc. (VVOS) has shown an average price growth of 154.92% over the past three years. It has received a score of 98 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Vivos Therapeutics, Inc. as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

question_mark
What is Vivos Therapeutics, Inc. (VVOS) stock price performance year to date (YTD)?

As of the latest data, Vivos Therapeutics, Inc. (VVOS) has a year-to-date price change of -56.45%. Over the past month, the stock has experienced a price change of -22.97%.

question_mark
Is Vivos Therapeutics, Inc. (VVOS) a profitable company?

Vivos Therapeutics, Inc. (VVOS) has a net income of -$15.41M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 60.1% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -110.27% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $14.5M, although specific revenue growth data is currently not available. The gross profit is $8.72M. Operating income is noted at -$19.08M. Furthermore, the EBITDA is -$18.58M.

question_mark
What is the market capitalization of Vivos Therapeutics, Inc. (VVOS)?

Vivos Therapeutics, Inc. (VVOS) has a market capitalization of $6.83M. The average daily trading volume is 162.16K, indicating the stock's liquidity and investor engagement.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.